Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
ESG
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
29/09/2023
Nykode Therapeutics Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer
27/09/2023
Nykode Therapeutics – presentation from Capital Markets Day in Oslo
25/09/2023
Nykode Therapeutics – Capital Markets Day in Oslo on September 27, 2023
20/09/2023
Nykode Therapeutics – Capital Markets Day in New York on September 20, 2023
14/09/2023
Nykode Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
